Buscar

Estamos realizando la búsqueda. Por favor, espere...

Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice

Abstract: Objective: Tofacitinib (TOF) is the first Janus kinase (JAK) inhibitor approved for psoriatic arthritis (PsA). It has shown efficacy in patients refractory to anti-tumor necrosis factor-? in randomized controlled trials (RCTs). Our aim was to assess efficacy and safety of TOF in clinical practice. Methods: This was an observational, open-label multicenter study of PsA patients treated with TOF due to inefficacy or adverse events of previous therapies. Outcome variables were efficacy, corticosteroid dose-sparing effect, retention rate, and safety. A comparative study of clinical features between our cohort of patients and those from the OPAL Beyond trial was performed. Results: There were 87 patients (28 women/59 men), with a mean age of 52.8 ± 11.4 years. All patients were refractory to biologic disease-modifying antirheumatic drugs (DMARDs) and/or to conventional synthetic DMARDs plus apremilast. TOF was started at 5 mg twice daily after a mean follow-up of 12.3 ± 9.3 years from PsA diagnosis. At first month, Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) decreased from median 4.8 (IQR 4.1-5.4) to 3.7 (IQR 2.8-4.7, P < 0.01), Disease Activity Index for Psoriatic Arthritis from median 28 (IQR 18.4-34.1) to 15.5 (IQR 10.1-25.7, P < 0.01), and C-reactive protein from median 1.9 (IQR 0.3-5.0) to 0.5 (IQR 0.1-2.2) mg/dL (P < 0.01). Also, TOF led to a significant reduction in prednisone dose. Mild adverse effects were reported in 21 patients (24.13%), mainly gastrointestinal symptoms. TOF retention rate at Month 6 was 77% (95% CI 65.2-86.3). Patients in clinical practice were older with longer disease duration and received biologic agents more commonly than those in the OPAL Beyond trial. Conclusion: Data from clinical practice confirm that TOF seems to be effective, rapid, and relatively safe in refractory PsA despite clinical differences with patients in RCTs.

 Fuente: J Rheumatol . 2021 Oct;48(10):1552-1558

 Editorial: The Journal of Rheumatology Publishing Company Limited

 Año de publicación: 2021

 Nº de páginas: 7

 Tipo de publicación: Artículo de Revista

 DOI: 10.3899/jrheum.201204

 ISSN: 0315-162X

 Url de la publicación: https://www.doi.org/10.3899/jrheum.201204

Autoría

GALÍNDEZ-AGIRREGOIKOA, EVA

DIANA PRIETO PEÑA

MARTÍN-VARILLAS, JOSÉ LUIS

JOVEN, BEATRIZ

RUSINOVICH, OLGA

MELERO-GONZÁLEZ, RAFAEL B

ORTIZ-SANJUAN, FRANCISCO

ALMODÓVAR, RAQUEL

ALEGRE-SANCHO, JUAN JOSÉ

MARTÍNEZ, ÁNGELS

SELLAS-FERNÁNDEZ, AGUSTÍ

MÉNDEZ, LARA

GARCÍA-VICUÑA, ROSARIO

BELÉN ATIENZA MATEO